Clinical and molecular characteristics of an outbreak caused by the pandemic (BI/NAP1/027) Clostridium difficile clone in a single center in Israel

Infection Control and Hospital Epidemiology

Volumn 35, Issue 10, 2014, Pages 1306-1308

  Wiener Well, Yonit ^a   Ben Chetrit, Eli ^a   Abed Eldaim, Mustafa ^a   Assous, Marc V ^a   Miller Roll, Tamar ^b   Adler, Amos ^b  

^a HEBREW UNIVERSITY   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CEPHALOSPORIN; CREATININE; METRONIDAZOLE; MOXIFLOXACIN; QUINOLONE DERIVATIVE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHARLSON COMORBIDITY INDEX; CLOSTRIDIUM DIFFICILE INFECTION; DEATH; DRUG TREATMENT FAILURE; FECES ANALYSIS; HOSPITAL INFECTION; HUMAN; ISRAEL; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; MORTALITY; NOTE; PANDEMIC; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; VERY ELDERLY; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; HUMANS; ISRAEL; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PANDEMICS; YOUNG ADULT;

EID: 84907187422     PISSN: 0899823X     EISSN: 15596834     Source Type: Journal    
DOI: 10.1086/678070     Document Type: Note

References (10)

1. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care–associated infections. N Engl J Med 2014;370:1198–1208.
2. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366: 1079–1084.
3. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene–variant strain of Clostridium difficile. N Engl J Med 2005;353:2433–2441.
4. Clements ACA, Magalhães RJS, Tatem AJ, Paterson DL, Riley TV. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010;10:395–304.
5. Alzahrani N, Johani SA. Emergence of a highly resistant Clostridium difficile strain (NAP/BI/027) in a tertiary care center in Saudi Arabia. Ann Saudi Med 2013;33:198–199.
6. Bishara J, Goldberg E, Madar-Shapiro L, Behor J, Samra Z. Molecular epidemiology of Clostridium difficile in a tertiary medical center in Israel: emergence of the polymerase chain reaction ribotype 027. Isr Med Assoc J 2011;13:338–341.
7. Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Approved Standard—Eighth Edition. Wayne, PA: CLSI, 2012.
8. Lemee L, Dhalluin A, Testelin S, et al. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (toxin A), and tcdB (toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 2004;42:5710–5714.
9. Persson S, Jensen JN, Olsen KEP. Multiplex PCR method for detection of Clostridium difficile tcdA, tcdB, cdtA, and cdtB and internal in-frame deletion of tcdC. J Clin Microbiol 2011;49: 4299–4300.
10. Kato H. Typing by sequencing the slpA gene of Clostridium difficile strains causing multiple outbreaks in Japan. J Med Microbiol 2005;54:167–171.